News Sarepta DMD gene therapy could improve patients' motor funct... Sarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase 1 trial showing an improvement in patients’
DMD Main Curing DMD: Travelling together to find a meaningful destina... For many years, Duchenne muscular dystrophy (DMD) was something of a forgotten disease.
Disease Spotlight Increase collaboration to widen access to DMD drugs, trials ... When it comes to fighting a rare disease like Duchenne muscular dystrophy (DMD), it’s a matter of strength in numbers.
News Pfizer axes development of Duchenne muscular dystrophy antib... Pfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy targets.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.